Collaborating with Patient Advocacy Groups to Educate the Marketplace
Strong relationships with advocacy groups are fundamental for educating the public on most recent medical happenings, especially on socially-sensitive conditions and treatment options. This comprehensive study analyzes the best practices from leading companies, narrates their findings, details valuable statistics and, examines ideal structures and skill sets for pharma groups that deal with advocacy groups and emerging trends and challenges in patient advocacy.
Insights are drawn from survey responses from a total of 58 research participants at 43 pharmaceutical companies. More than a dozen in-depth interviews were conducted to gather more detailed information pertinent to this study.
Sales and Marketing > Marketing Management d
Industries Profiled:
Pharmaceutical; Medical Device; Health Care; Consumer Products; Biotech; Diagnostic; Manufacturing; Research; Service; Technology; Media
Companies Profiled:
Abbott Laboratories; Baxter Healthcare; Solvay Pharmaceuticals; Vital Therapies; Triple S; Covidien; Savient Pharmaceuticals; Anesiva; Abaxis; Astellas; Philips Home Healthcare; Wyeth Pharmaceuticals; Thoratec Corporation; Amgen; Onyx Pharmaceuticals; Daiichi Sankyo; Purdue Pharma; Teva Pharmaceutical Industries Ltd; Ocimum Biosolutions; Genentech; Tibotec; King Pharmaceuticals; Allos Therapeutics; Johnson & Johnson; Theratechnologies; Infosys BPO; Discovery Chicago; Medrad; Talecris; IDS Canada; Becton Dickinson; GlaxoSmithKline ; Novartis; Takeda Pharmaceuticals; Genzyme; Boston Scientific; Synapse biomedical; Nupathe; Eisai; United Therapeutics; Bayer; Bristol-Myers Squibb; ANS
Study Snapshot
This performance benchmarking study probes best practices in working with Patient Advocacy groups, in particular groups that deal with socially sensitive conditions.
Follwing are the key topic areas discussed in-depth with supporting narratives, metrics and charts:
- Understanding the “advocacy” landscape
- Effective practices for working with potentially hostile patient advocacy groups
- Advocacy structures that work best
- Advocacy tools
- Critical competencies of Advocacy professionals
- Advocacy Lessons learned from socially sensitive or stigmatized disease areas
- Profiling Advocacy Group experience & expertise
Fifty-eight representatives from 43 companies shared their insights in the benchmark survey and more than a dozen agreed to interviews. Approximately half of the class represented top-50 bio-pharma companies.
Back to Top
Key Findings
Mapping The Advocacy Landscape To Know Where To Start:
Assess the landscape of advocacy and community-interest groups to understand the broad spectrum of players, special interests and possible collaborators. Different groups may prove more valuable collaborators at different stages of the product and disease lifecycle. Some groups will be friendly; some groups may prove hostile. Creating an advocacy “topographical” map is useful to strategic advocacy planning.
- Structuring High Performance Bio-Pharma Advocacy Groups:
Advocacy structures are rapidly evolving. Hybrid bio-pharma advocacy structures are most common. Internal advocacy organizations are evenly distributed across brand-focused groups, centralized groups, therapeutically focused groups and those with a mix of brand and therapeutic elements. Higher-functioning advocacy functions have developed a system for measuring the effectiveness of activities and relationships. Soft metrics or no metrics are most common.
Back to Top
Related Research:
Educating The Market: Creating Value Through Support of Continuing Medical Education
|
STUDY OVERVIEW
With limited information on actual return on investment for expenditures toward support of Continuing Medical Education activities, Pharmaceutical and Biotechnology companies are anxious to understand the value of CME support and strategies for ensuring investments provide appropriate impact on healthcare practitioner behaviors and patient outcomes... (ID PSM-223)
Companies Profiled: Alcon Laboratories, Sanofi-aventis, Wyeth Pharmaceuticals, TAP, more ...
Price: $5995.00 Free Excerpt Available
| |
|